Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$4.48
+14.9%
$2.98
$1.89
$4.70
$1.16B0.623.62 million shs11.57 million shs
Altimmune, Inc. stock logo
ALT
Altimmune
$4.08
+0.7%
$5.52
$2.90
$11.16
$328.48M0.473.38 million shs3.49 million shs
Harrow, Inc. stock logo
HROW
Harrow
$35.89
-0.7%
$30.13
$20.85
$59.23
$1.33B0.41500,180 shs482,017 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$29.41
-1.1%
$25.63
$16.16
$31.80
$1.21B0.75224,464 shs353,025 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-3.94%-8.24%+25.00%+61.16%+15.73%
Altimmune, Inc. stock logo
ALT
Altimmune
-3.11%-7.95%-41.22%-11.09%-45.93%
Harrow, Inc. stock logo
HROW
Harrow
+4.60%+15.21%+18.84%+50.65%+43.70%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-2.65%-4.53%+21.60%+71.95%+56.31%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.3336 of 5 stars
3.51.00.00.02.73.30.0
Altimmune, Inc. stock logo
ALT
Altimmune
2.2152 of 5 stars
3.41.00.00.03.11.70.6
Harrow, Inc. stock logo
HROW
Harrow
2.3876 of 5 stars
3.51.00.00.02.42.50.6
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
4.0499 of 5 stars
0.94.02.51.13.33.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
3.00
Buy$8.7595.75% Upside
Altimmune, Inc. stock logo
ALT
Altimmune
2.75
Moderate Buy$18.20346.08% Upside
Harrow, Inc. stock logo
HROW
Harrow
3.00
Buy$63.8377.86% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.83
Reduce$24.40-17.12% Downside

Current Analyst Ratings Breakdown

Latest ALT, HROW, PAHC, and ABCL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/14/2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$5.00 ➝ $10.00
7/11/2025
Harrow, Inc. stock logo
HROW
Harrow
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$76.00
7/10/2025
Altimmune, Inc. stock logo
ALT
Altimmune
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell
7/10/2025
Altimmune, Inc. stock logo
ALT
Altimmune
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$25.00 ➝ $15.00
7/7/2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/7/2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$5.00
7/7/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$25.00 ➝ $35.00
6/27/2025
Altimmune, Inc. stock logo
ALT
Altimmune
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
6/27/2025
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00
6/25/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$21.00 ➝ $26.00
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$28.83M46.27N/AN/A$3.58 per share1.25
Altimmune, Inc. stock logo
ALT
Altimmune
$20K16,546.44N/AN/A$1.74 per share2.34
Harrow, Inc. stock logo
HROW
Harrow
$199.61M6.60$0.14 per share252.67$1.95 per share18.41
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.02B1.17$2.04 per share14.45$6.34 per share4.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$162.86M-$0.56N/AN/AN/A-737.56%-15.98%-12.38%8/7/2025 (Estimated)
Altimmune, Inc. stock logo
ALT
Altimmune
-$95.06M-$1.26N/AN/AN/A-451,200.00%-65.44%-58.43%8/6/2025 (Estimated)
Harrow, Inc. stock logo
HROW
Harrow
-$17.48M-$0.56N/A89.73N/A-10.19%-25.01%-4.27%8/6/2025 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$2.42M$0.7837.7414.020.512.68%30.51%6.89%8/27/2025 (Estimated)

Latest ALT, HROW, PAHC, and ABCL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.3006N/AN/AN/A$0.00 millionN/A
8/7/2025Q2 2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.17N/AN/AN/A$7.55 millionN/A
8/6/2025Q2 2025
Harrow, Inc. stock logo
HROW
Harrow
$0.01N/AN/AN/A$64.23 millionN/A
5/13/2025Q1 2025
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million
5/8/2025Q1 2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.17-$0.15+$0.02-$0.15$7.12 million$4.24 million
5/8/2025Q1 2025
Harrow, Inc. stock logo
HROW
Harrow
$0.02-$0.38-$0.40-$0.50$57.00 million$47.83 million
5/7/2025Q3 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52$0.63+$0.11$0.51$352.41 million$347.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/AN/AN/AN/AN/A
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.63%N/A61.54%N/A

Latest ALT, HROW, PAHC, and ABCL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.122.52%6/4/20256/4/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/A
10.15
10.15
Altimmune, Inc. stock logo
ALT
Altimmune
N/A
15.85
15.85
Harrow, Inc. stock logo
HROW
Harrow
2.01
0.91
0.85
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.67
2.91
1.23

Institutional Ownership

CompanyInstitutional Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
61.42%
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
Harrow, Inc. stock logo
HROW
Harrow
72.76%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%

Insider Ownership

CompanyInsider Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
28.90%
Altimmune, Inc. stock logo
ALT
Altimmune
4.10%
Harrow, Inc. stock logo
HROW
Harrow
15.16%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
500298.42 million212.18 millionOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
5081.11 million77.78 millionOptionable
Harrow, Inc. stock logo
HROW
Harrow
18036.69 million31.12 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1,94040.53 million20.24 millionOptionable

Recent News About These Companies

Best Growth Stocks to Buy for July 17th
Best Growth Stocks to Buy for July 15th
PAHC Phibro Animal Health Corporation - Seeking Alpha
Best Growth Stocks to Buy for July 10th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbCellera Biologics stock logo

AbCellera Biologics NASDAQ:ABCL

$4.48 +0.58 (+14.87%)
Closing price 04:00 PM Eastern
Extended Trading
$4.50 +0.02 (+0.47%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Altimmune stock logo

Altimmune NASDAQ:ALT

$4.08 +0.03 (+0.74%)
Closing price 04:00 PM Eastern
Extended Trading
$4.10 +0.02 (+0.49%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Harrow stock logo

Harrow NASDAQ:HROW

$35.89 -0.25 (-0.69%)
Closing price 04:00 PM Eastern
Extended Trading
$36.60 +0.70 (+1.96%)
As of 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$29.41 -0.32 (-1.08%)
Closing price 04:00 PM Eastern
Extended Trading
$29.44 +0.03 (+0.10%)
As of 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.